MRI Interventions Inks Collaboration Deal with Acoustic MedSystems

MRI Interventions (OTCQB:MRIC) signed a licensing and collaborating agreement with Acoustic MedSystems.
As quoted in the press release:

Under the agreement, MRI Interventions and AMS will co-develop real-time, MRI-guided ultrasonic ablation therapies with an initial focus on the treatment of pancreatic cancer.  Development of these therapies will further expand the capabilities and addressable market for MRI Interventions’ revolutionary MRI-guided surgical platform.

Pancreatic cancer is a debilitating form of cancer, with over 50,000 patients diagnosed each year in the United States.  In approximately half of these patients, the cancer has metastasized to other locations in the body, and is not treatable surgically.  In cases where the cancer has not metastasized, the tumor is often complex in shape, location, and structure. Due to these complexities, it is estimated that surgeons are unable to surgically resect these otherwise local pancreatic tumors in approximately 15,000 – 20,000 patients per year.  MRI Interventions and AMS believe an MRI-guided ultrasound ablation therapy can provide a promising, new treatment approach for these patients.

Click here to read the full press release.

Source: globenewswire.com